The US FDA has approved ceftobiprole medocaril sodium to treat Staphylococcus aureus bloodstream infections in adults, including those with right-sided infective endocarditis, as well as acute bacterial skin and skin structure infections in adults. Additionally, the antibiotic is approved for use in pediatric patients aged three months to less than 18 years with community-acquired bacterial pneumonia. Clinical trial For treating Staphylococcus aureus bloodstream infections (bacteremia) In a randomized, controlled, double-blind, multinational, multicenter trial, researchers assessed the efficacy of ceftobiprole medocaril sodium compared to a combination of daptomycin plus optional aztreonam (the comparator).
The trial involved 390 subjects, where 192 subjects received ceftobiprole medocaril sodium and 198 received the comparator. The primary measure of efficacy was overall success,…
